News

€1bn alliance for AMD
Enlarge image

BusinessSwitzerland

€1bn alliance for AMD

22.08.2012 - US-pharma Allergan and Swiss biotech Molecular Partners have formed an exclusive alliance to develop a treatment for Age Related Macular Degeneration (AMD) worth €1.1 bn.

Allergan agreed to pay €55m in upfront payments, Molecular Partners is eligible to receive additional success-based payments that could sum up to more than €1 bn. The partnership consists of two separate agreements.

The first is an exclusive license agreement for the design, development and commercialization of a potent dual anti-VEGF-A/PDGF-B DARPin and corresponding backups for the treatment of AMD and related conditions. Under the license agreement, Allerganand Molecular Partners will work together to develop MP0260 through human proof of concept, at which point Molecular Partners has the option to co-fund Allergan's development costs in exchange for a significant royalty step up.

The second agreement is an exclusive discovery alliance agreement under which the parties will collaborate to design and develop DARPins against selected targets that are implicated in causing serious diseases of the eye. During the research phase, Allergan has the right to exercise three options to exclusively license collaboration compounds for ophthalmology. Upon execution of each option, Allergan will pay Molecular Partners an option exercise fee and be solely responsible for all downstream development, manufacturing, and commercialisation activities.

Zurich-based Molecular Partners is a privately-owned biotech company focusing on the research, development and commercialisation of small proteins called DARPins. Allergan, the maker of the popular anti-wrinkle treatment Botox, has more than 10,000 employees in more than 100 countries. MP0260 is a DARPin-based, small therapeutic protein with dual activity. It inhibits with high potency and selectivity all relevant forms of the two growth factors vascular endothelial growth factor A (VEGF-A) and platelet-derived growth factor B (PDGF-B). The molecule is currently being explored for its use in wet age-related macular degeneration (AMD). Its high efficacy and long intravitreal PK have been demonstrated in various preclinical models. Molecular Partners and Allergan know each other well as this is already their second agreement.

http://www.european-biotechnology-news.com/news/news/2012-03/eur1bn-alliance-for-amd.html

Clinical TrialsEUFrancePortugal

31.05.2016 The European Medicines Agency (EMA) means to increase first-in-man trial safety. Following the death of a volunteer in a Phase I trial earlier this year, the European Medicines Agency has started a review of the guidelines for first-in-man studies.

AwardFinlandEU

27.05.2016 The Finnish Technology Academy has awarded US-American innovator Frances Arnold the 2016 Millennium Technology Prize, worth €1m. Arnold is a pioneer in the field of directed evolution.

OncologyUK

26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Basel (CH)

Chemspec Europe 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • NORDIC NANOVECTOR (N)27.10 NOK10.61%

FLOP

  • THERAMETRICS (CH)0.02 CHF-33.33%
  • 4SC (D)2.38 EUR-8.11%
  • RENEURON (UK)3.38 GBP-3.43%

TOP

  • GALAPAGOS (B)51.60 EUR30.0%
  • NICOX (F)10.95 EUR28.1%
  • GENMAB (DK)1194.00 DKK24.0%

FLOP

  • THERAMETRICS (CH)0.02 CHF-33.3%
  • 4SC (D)2.38 EUR-27.9%
  • MOBERG PHARMA (S)38.70 SEK-20.4%

TOP

  • KARO BIO (S)30.30 SEK1906.6%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • NICOX (F)10.95 EUR488.7%

FLOP

  • BB BIOTECH (D)44.70 EUR-84.5%
  • BIOTEST (D)17.05 EUR-78.3%
  • EVOCUTIS (UK)0.05 GBP-77.3%

No liability assumed, Date: 31.05.2016